Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 5,567 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Degenerative Conditions, Neurologic Clear all
Completed Phase 4 Interventional Results available

Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management

NCT03103919
View directory record Official record
Conditions
Parkinson´s Disease
Interventions
Kinesia-ONE™, Kinesia-360™, Rotigotine
Device · Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Fountain Valley, California • Boca Raton, Florida • Winfield, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 25, 2026, 4:43 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

NCT03207867
View directory record Official record
Conditions
NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MSS, Microsatellite Stable Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma, mCRPC, Metastatic Castration Resistant Prostate Cancer
Interventions
NIR178, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Santa Monica, California • Tampa, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 25, 2026, 4:43 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

NCT03068754
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Acthar, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 25, 2026, 4:43 PM EDT
Terminated Phase 2 Interventional Results available

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

NCT04579666
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
Pegcetacoplan (APL-2), Placebo
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 25, 2026, 4:43 PM EDT
Active, not recruiting Not applicable Interventional

High Frequency Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease

NCT04042922
View directory record Official record
Conditions
Alzheimer Disease
Interventions
GENUS device (Active Settings), GENUS device (Sham Settings)
Device
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
50 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 25, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies

NCT02702102
View directory record Official record
Conditions
Diffuse Lewy Body Disease, Dementia With Lewy Bodies, Parkinson's Disease Dementia
Interventions
11C-PBR28
Drug
Lead sponsor
Columbia University
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 25, 2026, 4:43 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Wearable Airbag Technology to Mitigate Falls in Individuals With High Fall Risk

NCT05076565
View directory record Official record
Conditions
Stroke, Parkinson Disease, Lower Limb Amputation Knee, Fall Injury, Fall Patients, Falling
Interventions
Airbag Belt Fall Protection System
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 25, 2026, 4:43 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

NCT00727194
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
eculizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 25, 2026, 4:43 PM EDT
Recruiting Not applicable Interventional

Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's Disease

NCT07207122
View directory record Official record
Conditions
Parkinson Disease
Interventions
Gen0Bh Transcranial Focused Ultrasound System (Active), Gen0Bh Transcranial Focused Ultrasound System (Sham)
Device
Lead sponsor
Sanmai Technologies PBC dba Sanmai
Industry
Eligibility
22 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Tucson, Arizona • Santa Monica, California • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 25, 2026, 4:43 PM EDT
Enrolling by invitation Not applicable Interventional

TMS in Anxiety-Parkinson's Disease

NCT06999330
View directory record Official record
Conditions
Parkinsons Disease (PD), Anxiety
Interventions
Theta burst stimulation active coil, Sham coil
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
40 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 25, 2026, 4:43 PM EDT
Completed Phase 4 Interventional Results available

Anti-Diabetic Medications to Fight PD and LBD

NCT06263673
View directory record Official record
Conditions
Lewy Body Dementia, Parkinson Disease
Interventions
Sitagliptin, Dapagliflozin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 25, 2026, 4:43 PM EDT
Completed Early Phase 1 Interventional

Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1

NCT00657202
View directory record Official record
Conditions
Neurofibromatosis Type 1, Cutaneous Neurofibromas
Interventions
Ranibizumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 25, 2026, 4:43 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

NCT04777331
View directory record Official record
Conditions
Parkinsons Disease
Interventions
Prasinezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 25, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

NCT02386553
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Nusinersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
0 Weeks to 6 Weeks
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 25, 2026, 4:43 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy

NCT07362875
View directory record Official record
Conditions
Myotonic Dystrophy
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 25, 2026, 4:43 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Spectroscopy in Parkinson Disease

NCT01005030
View directory record Official record
Conditions
Parkinson Disease
Interventions
Blood draw
Other
Lead sponsor
Molecular Biometrics, Inc.
Industry
Eligibility
46 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2009 · Synced Oct 25, 2026, 4:43 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Combating Alzheimer's Through Sleep and Exercise

NCT04855630
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment (MCI), Cognitively Unimpaired, Alzheimer's Dementia (AD)
Interventions
Elemind Neuromodulation Headband, Exercise Routine
Device · Other
Lead sponsor
University of Miami
Other
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 25, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

NCT00790400
View directory record Official record
Conditions
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Interventions
Everolimus (RAD001), Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 25, 2026, 4:43 PM EDT
Terminated Phase 1 Interventional

Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure

NCT01292694
View directory record Official record
Conditions
Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions
Losartan, Captopril, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 25, 2026, 4:43 PM EDT
Recruiting Not applicable Interventional

Changes in Movement, Fitness, and Quality of Life in People With Parkinson's Disease After Different Exercise Programs

NCT07221266
View directory record Official record
Conditions
Parkinson Disease (PD)
Interventions
Guided Cycling, Non-Contact Boxing, Traditional Physical Therapy Program (Standard of Care)
Behavioral
Lead sponsor
University of Texas, El Paso
Other
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 25, 2026, 4:43 PM EDT
Withdrawn Not applicable Interventional

Fatigue in Patients With Amyotrophic Lateral Sclerosis

NCT04468191
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Dysphagia, Dyspnea, Respiration Disorders
Interventions
Experimental expiratory muscle strength training (EMST), Sham expiratory muscle strength training (EMST)
Device
Lead sponsor
Cara Donohue
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 25, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Synapse Project

NCT04871074
View directory record Official record
Conditions
Alzheimer Disease
Interventions
UCB-J, MRI Scan, PET Scan
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 25, 2026, 4:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

NCT06064890
View directory record Official record
Conditions
Frontotemporal Dementia, FTD, FTD-GRN, Dementia, Frontotemporal
Interventions
Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101
Procedure · Genetic
Lead sponsor
AviadoBio Ltd
Industry
Eligibility
30 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
3
States / cities
Columbus, Ohio • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 25, 2026, 4:43 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Galantamine Executive Function in Parkinson's Disease

NCT00211588
View directory record Official record
Conditions
Parkinson's Disease
Interventions
galantamine
Drug
Lead sponsor
Memorial Hospital of Rhode Island
Other
Eligibility
60 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Pawtucket, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Oct 25, 2026, 4:43 PM EDT